Eli Lilly stock steadies into Monday as $55 million ABL Bio funding keeps pipeline in focus
NEW YORK, December 28, 2025, 20:34 ET — Market closed Eli Lilly shares ended the holiday week little changed after South Korean biotech ABL Bio said it would receive $55 million in funding from the U.S. drugmaker under a research collaboration. PR Newswire The funding is small by Lilly standards, but it underscores how closely investors are tracking the company’s dealmaking and research spending as it looks to extend growth beyond its blockbuster diabetes and obesity franchise. PR Newswire That focus has sharpened into year-end as traders look ahead to 2026, when regulatory decisions and clinical readouts across Lilly’s obesity